Nuclear Medicine Training: Skills and Competencies Required for Practice in the 21st Century

Ismaheel O. Lawal

doi:10.1055/s-0043-1769588

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY 4.0 · World J Nucl Med 2023; 22(02): 075-077
DOI: 10.1055/s-0043-1769588

Editorial

Nuclear Medicine Training: Skills and Competencies Required for Practice in the 21st Century

Ismaheel O. Lawal

¹Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States

²Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa

References
1 Vaz SC, Oliveira F, Herrmann K, Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol 2020; 93 (1110): 20200095
2 Harolds JA, Oates ME, Guiberteau MJ, Ghesani M, Scanlon MH, Iagaru AH. New training pathways to dual certification in nuclear medicine and radiology. J Nucl Med 2015; 56 (06) 17N-18N
3 Segall GM, Grady EE, Fair JR, Ghesani MV, Gordon L. Nuclear medicine training in the United States. J Nucl Med 2017; 58 (11) 1733-1734
4 Neilly B, Dizdarevic S, Prvulovich L, Buscombe J, Lewington V. Nuclear medicine training and practice in the UK. Eur J Nucl Med Mol Imaging 2016; 43 (04) 800-803
5 Velleman T, Kwee TC, Dierckx RAJO, Ongena YP, Noordzij W. The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists. Eur J Nucl Med Mol Imaging 2022; 49 (09) 3016-3022
6 Muylle K, Maffioli L. Nuclear medicine training in Europe: “all for one, one for all”. J Nucl Med 2017; 58 (12) 1904-1905
7 Johannes C, Ken H. The disappearing act of nuclear medicine in the Netherlands: just a new trick by the great Harry Houdini?. J Nucl Med 2021; 62 (07) 903-904
8 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
9 Sartor O, de Bono J, Chi KN. et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385 (12) 1091-1103
10 Parker C, Nilsson S, Heinrich D. et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-223
11 Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern A, Lawal IO. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging 2021; 49 (01) 30-46
12 Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K. et al. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? J Nucl Med. Epub ahead of print on Apr 13, 2023
13 Lee ST, Emmett LM, Pattison DA. et al. The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective. J Nucl Med 2022; 63 (06) 819-822
14 Farolfi A, Lima GM, Oyen W, Fanti S. Molecular imaging and theranostics-a multidisciplinary approach. Semin Nucl Med 2019; 49 (04) 247-254
15 Bodei L, Chiti A, Modlin IM, Scott AM, Schöder H. The path to the future: education of nuclear medicine therapeutic specialists as responsible physicians. J Nucl Med 2019; 60 (12) 1663-1664